RhumbLine Advisers
CTMX icon

RhumbLine Advisers’s CytomX Therapeutics CTMX Stock Holding History

RhumbLine Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,291
Closed -$1.57K – 4228
2024
Q2 		$1.57K Hold
1,291
– – ﹤0.01% 4204
2024
Q1 		$2.81K Hold
1,291
– – ﹤0.01% 4054
2023
Q4 		$2K Hold
1,291
– – ﹤0.01% 4092
2023
Q3 		$1.67K Hold
1,291
– – ﹤0.01% 4128
2023
Q2 		$2.22K Buy
+1,291
New +$2.14K ﹤0.01% 4203
2022
Q2 		– Sell
-67,376
Closed -$180K – 3124
2022
Q1 		$180K Buy
67,376
+428
+0.6% +$1.64K ﹤0.01% 2782
2021
Q4 		$290K Sell
66,948
-985
-1% -$5.77K ﹤0.01% 2716
2021
Q3 		$346K Buy
67,933
+3,757
+6% +$20.1K ﹤0.01% 2706
2021
Q2 		$406K Buy
64,176
+3,190
+5% +$24.8K ﹤0.01% 2656
2021
Q1 		$471K Buy
60,986
+1,845
+3% +$14.6K ﹤0.01% 2521
2020
Q4 		$387K Buy
59,141
+3,310
+6% +$23.6K ﹤0.01% 2550
2020
Q3 		$371K Sell
55,831
-7,790
-12% -$57.8K ﹤0.01% 2427
2020
Q2 		$530K Buy
63,621
+2,956
+5% +$27.5K ﹤0.01% 2315
2020
Q1 		$465K Sell
60,665
-1,690
-3% -$11.8K ﹤0.01% 2193
2019
Q4 		$518K Buy
62,355
+1,147
+2% +$7.74K ﹤0.01% 2341
2019
Q3 		$452K Buy
61,208
+921
+2% +$9.09K ﹤0.01% 2368
2019
Q2 		$676K Buy
60,287
+2,500
+4% +$26.2K ﹤0.01% 2238
2019
Q1 		$621K Sell
57,787
-1,356
-2% -$20K ﹤0.01% 2236
2018
Q4 		$893K Buy
59,143
+21,402
+57% +$318K ﹤0.01% 2064
2018
Q3 		$698K Buy
37,741
+689
+2% +$15.7K ﹤0.01% 2148
2018
Q2 		$847K Buy
37,052
+8,100
+28% +$207K ﹤0.01% 2086
2018
Q1 		$824K Buy
28,952
+200
+0.7% +$5.71K ﹤0.01% 2027
2017
Q4 		$607K Sell
28,752
-4,245
-13% -$88K ﹤0.01% 2159
2017
Q3 		$600K Buy
32,997
+480
+1% +$7.49K ﹤0.01% 2221
2017
Q2 		$504K Buy
32,517
+10,607
+48% +$160K ﹤0.01% 2300
2017
Q1 		$378K Buy
21,910
+872
+4% +$11.5K ﹤0.01% 2384
2016
Q4 		$231K Buy
21,038
+3,812
+22% +$46.2K ﹤0.01% 2615
2016
Q3 		$270K Buy
17,226
+2,300
+15% +$27.8K ﹤0.01% 2534
2016
Q2 		$152K Buy
+14,926
New +$170K ﹤0.01% 2830

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

RhumbLine Advisers's CTMX Position: Q3 2024 in Review

RhumbLine Advisers sold out of CytomX Therapeutics (CTMX) in Q3 2024, closing a stake of 1,291 shares — an estimated $1.57K sold.

RhumbLine Advisers first reported a position in CTMX in Q2 2016 and held it in 29 quarters. The position peaked at $893K in Q4 2018. 69 funds tracked by Wall St. Rank hold CTMX as of Q3 2024.

  • RhumbLine Advisers reported no remaining CytomX Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 1,291 CytomX Therapeutics shares in Q3 2024, an estimated $1.57K.
  • RhumbLine Advisers first reported a position in CytomX Therapeutics in Q2 2016 and held it in 29 quarters.
  • RhumbLine Advisers's CytomX Therapeutics position peaked at $893K in Q4 2018.
  • 69 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.